References

1. Tolar J, Hippen KL, Blazar BR (2009) Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. Br J Haematol 147: 200-206. View
2. Read EJ (1996) Quality assurance for cell processing: no more blind faith. Transfusion 36: 1-4. View
3. LeMaistre CF, Loberiza FR Jr (2005) What is quality in a transplant program? Biol Blood Marrow Transplant 11: 241-246. View
4. Caunday O, Bensoussan D, Decot V, Bordigoni P, Stoltz JF (2009) Regulatory aspects of cellular therapy product in Europe: JACIE accreditation in a processing facility. Biomed Mater Eng 19: 373-379. View
5. Cutler C, Antin JH (2005) An overview of hematopoietic stem cell transplantation. Clin Chest Med 26: 517-527. View
6. Cohen JL, Boyer O (2006) The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. Curr Opin Immunol 18: 580-585. View
7. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, et al. (2006) High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108: 1291-1297. View
8. Pabst C, Schirutschke H, Ehninger G, Bornhäuser M, Platzbecker U (2007) The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin Cancer Res 13: 2916-2922. View
9. Hoffmann P, Ermann J, Edinger M (2005) CD4+CD25+ regulatory T cells in hematopoietic stem cell transplantation. Curr Top Microbiol Immunol 293: 265-285. View
10. Daniele N, Scerpa MC, Landi F, Caniglia M, Miele MJ, et al. (2011) T(reg) cells: collection, processing, storage and clinical use. Pathol Res Pract 207: 209-215. View
11. Handgretinger R (2012) New approaches to graft engineering for haploidentical bone marrow transplantation. Semin Oncol 39: 664-673. View
12. Daniele N, Scerpa MC, Caniglia M, Bernardo ME, Rossi C, et al. (2012) Transplantation in the onco-hematology field: focus on the manipulation of αβ and γδ cells. Pathol Res Pract 208: 67-73. View
13. Anasetti C, Etzioni R, Petersdorf EW, Martin PJ, Hansen JA (1995) Marrow transplantation from unrelated volunteer donors. Annu Rev Med 46: 169- 179. View
14. Kanda J, Chao NJ, Rizzieri DA (2010) Haploidentical transplantation for leukemia. Curr Oncol Rep 12: 292-301. View
15. Chaleff S, Otto M, Barfield RC, Leimig T, Iyengar R, et al. (2007) A largescale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 9: 746-754. View
16. Passweg JR, Koehl U, Uharek L, Meyer-Monard S, Tichelli A (2006) Naturalkiller- cell-based treatment in haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 19: 811-824. View
17. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, et al. (2007) Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 109: 2871-2877. View
18. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, et al. (2006) Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 134: 64-76. View
19. Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M (2008) Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 40: 63-67. View
20. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854. View
21. Spitzer TR, Dey BR, Chen YB, Attar E, Ballen KK (2012) The expanding frontier of hematopoietic cell transplantation. Cytometry B Clin Cytom 82: 271-279. View
22. THOMAS ED, LOCHTE HL Jr, LU WC, FERREBEE JW (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257: 491-496. View
23. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS (2009) The role of B cells in the pathogenesis of graft-versus-host disease. Blood 114: 4919-4927. View
24. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, et al. (2012) Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 119: 6145-6154. View
25. Bouazzaoui A, Spacenko E, Mueller G, Miklos S, Huber E, et al. (2009) Chemokine and chemokine receptor expression analysis in target organs of acute graft-versus-host disease. Genes Immun 10: 687-701. View
26. Castor MG, Pinho V, Teixeira MM (2012) The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics. Front Pharmacol 3: 23. View
27. Abraham S, Choi JG, Ye C, Manjunath N, Shankar P (2015) IL-10 exacerbates xenogeneic GVHD by inducing massive human T cell expansion. Clin Immunol 156: 58-64. View